Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women

Maturitas

Volumn 42, Issue 1, 2002, Pages 77-84

  Christodoulacos, G ^a   Panoulis, C ^a   Botsis, D ^a   Rizos, D ^a   Kassanos, D ^a   Creatsas, G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

HRT; Raloxifene; Sonography; Transvaginal sonographic monitoring

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM; ESTRADIOL PLUS NORETHISTERONE ACETATE; RALOXIFENE; STATIN; THYROXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; ENDOMETRIUM BIOPSY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; HYSTEROSCOPY; NORMAL HUMAN; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; UTERUS; UTERUS BLEEDING;

ADMINISTRATION, ORAL; ADULT; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIUM; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; UTERUS;

EID: 0037140678     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(02)00027-0     Document Type: Article

References (26)

1. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women
2. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users
3. Postemenopausal hormone replacement therapy: Some common and uncommon questions
4. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
5. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone
6. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate
7. Effects of hormone replacement therapy on the endometrium and lipid parameters: A review of randomized clinical trials, 1985-1995
8. Does progestogen protect the endometrium
9. Cancer risk in women receiving estrogen-progestin replacement therapy
10. Hormone replacement therapy and endometrial cancer risk: A meta-analysis
11. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestogen therapy in postmenopausal women
12. Raloxifene: A selective estrogen receptor modulator
13. Transvaginal sonography of the endometrium in postmenopausal women
14. Transvaginal sonography of the endometrium in postmenopausal women: Monitoring the effect of hormone replacement therapy
15. Uterine findings by transvaginal sonography during percutaneous estrogen treatment in postmenopausal women
16. Endometrial thickness assessed by transvaginal ultrasound insufficiently predicts occurrence of hyperplasia during unopposed estrogen use
17. Transvaginal ultrasonography for identifying endometrial pathology in postmenoapusal women
18. Raloxifene does not cause stimulatory effects on the uterus in healthy postmenopausal women
19. Effects of tamoxifen on uterus and ovaries of postmenopausal. In a randomized breast cancer prevention trial
20. Bleeding patterns in recent postmenopausal outpatients with uterine myomas: Comparison between two regimens of HRT
21. Endometrial cancer after combined hormone replacement therapy
22. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women
23. Optimizing continuous-combined hormone replacement therapy for postmenopausal women: A comparison of six different treatment regimens
24. A 12-month comparative study of raloxifene, estrogen and placebo on the postmenopausal endometrium
25. A multicentre randomized trial to compare the uterine effects of raloxifene (Evista) with a continuous combined hormone replacement therapy (Kliogest); Results from Euralox 1
26. Adverse events reported by postmenopausal women in controlled trials with raloxifene